Protagonist Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protagonist Therapeutics, Inc. on August 7, 2018, reporting events occurring on August 6, 2018. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
The filing details a capital raise transaction rather than periodic financial performance metrics such as revenue or operating profit.
- Common Stock Offering: Sale of up to 2,750,000 shares at $8.00 per share.
- Gross Proceeds: Approximately $22.0 million (before offering expenses).
- Warrant Issuance: Concurrent private placement of warrants to purchase 2,750,000 shares total.
- Warrant Structure:
- 1,375,000 Class A Warrants with an exercise price of $10.00 per share.
- 1,375,000 Class B Warrants with an exercise price of $15.00 per share.
- Term: Exercisable from issuance date until the five-year anniversary of the closing date.
The filing text does not provide clear values for current revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement and the issuance of new equity and warrants, which will increase the company's cash position upon closing and increase the number of outstanding shares and potential dilution.
Outlook, Risks, and Unusual Items
Management Commentary: The company utilized an effective shelf registration statement (Form S-3) for the common stock and a private placement exemption (Section 4(a)(2) and Rule 506(b)) for the warrants. Purchasers are accredited investors or qualified institutional buyers.
Risks and Contingencies: The transaction involves potential dilution to existing shareholders. Warrants are subject to adjustment for stock dividends, splits, and recapitalizations. The company expects to file the full Purchase Agreement as an exhibit to its upcoming Form 10-Q for the quarter ending September 30, 2018.
Key Facts for Investor Verification
- Verify the final closing date and actual gross proceeds received after deducting offering expenses.
- Confirm the exact number of shares issued and the final share count post-closing.
- Review the definitive Purchase Agreement and Warrant forms (Exhibits 4.1, 4.2, and 4.3) for specific anti-dilution provisions and cashless exercise terms.
- Monitor the upcoming Form 10-Q for the impact of this transaction on the company's cash balance and liquidity.